Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma

Blood Cancer J. 2017 Oct 6;7(10):e615. doi: 10.1038/bcj.2017.95.

Authors

Y Wang^{1

2}, A J Yee^{2

3}, C Sirard⁴, S Landau⁴, N Raje^{2

3}, U Mahmood^{1

2}

Affiliations

¹ Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
⁴ Leap Therapeutics, Inc., Cambridge, MA, USA.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Biomarkers
Bone and Bones / pathology*
Female
Homeostasis
Humans
Intercellular Signaling Peptides and Proteins / pharmacology
Intercellular Signaling Peptides and Proteins / therapeutic use*
Male
Middle Aged
Multiple Myeloma / complications*
Multiple Myeloma / diagnostic imaging
Multiple Myeloma / drug therapy
Positron-Emission Tomography / methods*
Sodium Fluoride / chemistry*

Substances

Biomarkers
DKK1 protein, human
Intercellular Signaling Peptides and Proteins
Sodium Fluoride